Comprehensive Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Analysis 2024: Size, Share, And Key Trends
Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
What is the Expected Growth Rate of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market from 2024 to 2033?
The paroxysmal nocturnal hemoglobinuria (PNH) market has grown rapidly in recent years. It will increase from $3.84 billion in 2023 to $4.24 billion in 2024, at a CAGR of 10.5%. The growth is driven by rising demand for treatment, increased disposable incomes, government initiatives, and higher healthcare expenditure.
The paroxysmal nocturnal hemoglobinuria (PNH) market is projected to grow to $6.09 billion in 2028, at a CAGR of 9.5%. This growth is attributed to the aging population, increased demand for self-administered treatments, improved healthcare access, and the rise in comorbidities. Trends include digital health technologies, gene therapy development, new treatments, and early interventions.
Claim Your Free Sample of the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp
The growing incidence of blood and bone marrow disorders is expected to propel the paroxysmal nocturnal hemoglobinuria (PNH) market. PNH, a rare blood disorder linked to bone marrow failure, impacts blood cell production and immune function. The Leukemia Foundation estimated in June 2021 that over 110,000 Australians had blood disorders, a figure projected to surpass 275,000 by 2035. The Australian Institute of Health and Welfare’s 2021 Cancer Data report recorded over 50 daily diagnoses of blood cancers in 2021, up from 47 in 2020. As a result, rising cases of blood and bone marrow disorders are expected to drive the PNH market.
1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types
2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types
3) By End Use: Hospitals, Clinics, Other End Users
In the paroxysmal nocturnal hemoglobinuria (PNH) market, companies are developing new drugs and therapies. Apellis Pharmaceuticals Inc., a US-based biopharmaceutical company, received FDA approval for EMPAVELI (pegcetacoplan) in May 2021. EMPAVELI is the first targeted C3 therapy for PNH and aims to enhance the lives of PNH patients by increasing hemoglobin levels and reducing the need for blood transfusions. The company also launched ApellisAssist, a program offering comprehensive support for EMPAVELI patients.
Order Now for Fast Delivery of Your Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Report!
North America was the largest region in the advanced glass market in 2023. The regions covered in the advanced glass market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the paroxysmal nocturnal hemoglobinuria (pnh) market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Include
1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Executive Summary
2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Segments
3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Size And Template Market Growth Rate
4. Key Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Trends
5. Major Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Drivers
……
25. Key Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market
26. Top Paroxysmal Nocturnal Hemoglobinuria (PNH) Companies
27. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Opportunities And Strategies
28. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Acute Myeloid Leukemia Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report
Leukemia Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Chronic Lymphocytic Leukemia Treatment Global Market Report 2024
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
